THV 01

Drug Profile

THV 01

Alternative Names: THV01; THV01-1; THV01-2

Latest Information Update: 01 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator THERAVECTYS
  • Class AIDS vaccines; Dendritic cell vaccines; Gene therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II HIV infections

Most Recent Events

  • 01 Dec 2017 THV 01 is still in phase I/II trials for HIV infections (Theravectys website, December 2017)
  • 23 Mar 2015 THERAVECTYS completes phase I/II trials in HIV infections in Belgium and France (NCT02054286)
  • 03 Dec 2014 THERAVECTYS has patent protection for lentiviral vector technology in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top